Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
As Viatris Discloses ‘Challenging’ Orencia Biosimilar Is Part Of Pipeline Again
Executive Summary
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
You may also be interested in...
Viatris Plots January Investor Day To Flesh Out Longer-Term Roadmap
Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.
Regeneron Predicts Impending Biosimilar Lucentis Impact On Eylea Brand
Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.
Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.